MCID: CRC006
MIFTS: 57

Carcinoid Syndrome

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Carcinoid Syndrome

MalaCards integrated aliases for Carcinoid Syndrome:

Name: Carcinoid Syndrome 19 58 75 16 31 33
Carcinoid Tumor 19 16 71
Malignant Carcinoid Syndrome 58 71
Carcinoid Tumor No Icd-O Subtype 71
Carcinoid Tumor Syndrome 19
Argentaffinoma Syndrome 33
Carcinoid Tumors 41

Characteristics:


Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare endocrine diseases


Summaries for Carcinoid Syndrome

MedlinePlus: 41 Carcinoid tumors are rare, slow-growing cancers. They usually start in the lining of the digestive tract or in the lungs. They grow slowly and don't produce symptoms in the early stages. As a result, the average age of people diagnosed with digestive or lung carcinoids is about 60. In later stages the tumors sometimes produce hormones that can cause carcinoid syndrome. The syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing. Surgery is the main treatment for carcinoid tumors. If they haven't spread to other parts of the body, surgery can cure the cancer.

MalaCards based summary: Carcinoid Syndrome, also known as carcinoid tumor, is related to appendix carcinoid tumor and carcinoid tumors, intestinal. An important gene associated with Carcinoid Syndrome is SDHD (Succinate Dehydrogenase Complex Subunit D), and among its related pathways/superpathways are Class A/1 (Rhodopsin-like receptors) and Signal Transduction. The drugs Cyproheptadine and Histamine have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and small intestine, and related phenotypes are night sweats and small intestine carcinoid

Orphanet: 58 A rare neoplastic disease characterized by the occurrence of a hormonal syndrome resulting from secretion of humoral factors (including polypeptides, vasoactive amines, and prostaglandins) from a functional neuroendocrine tumor (particularly from the midgut), typically manifesting with increased bowel movements and diarrhea, episodic vasoactive flushes (particularly of the face), hypotension, tachycardia, venous telangiectasia, dyspnea, and bronchospasms, as well as long-term fibrotic changes in the mesentery, retroperitoneum, and of the cardiac valves.

GARD: 19 Carcinoid syndrome refers to a group of symptoms that are associated with carcinoid tumors (rare, slow-growing tumors that occur most frequently in the gastroinestinal tract or lungs). Affected people may experience skin flushing, abdominal pain, diarrhea, difficulty breathing, rapid heart rate, low blood pressure, skin lesions on the face (telangiectasias), and wheezing. In later stages, Carcinoid syndrome may damage the heart valves. The condition occurs when the carcinoid tumor secretes serotonin or other chemicals into the bloodstream.

Wikipedia: 75 Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary... more...

Related Diseases for Carcinoid Syndrome

Diseases related to Carcinoid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 918)
# Related Disease Score Top Affiliating Genes
1 appendix carcinoid tumor 32.0 SYP ENO2 CHGA
2 carcinoid tumors, intestinal 32.0 SYP SST ENO2 CHGA
3 serotonin syndrome 31.2 SST PYY IFNA2 GHRH CHGA
4 goblet cell carcinoid 31.1 ENO2 CHGA
5 mature teratoma 30.7 SYP ENO2
6 pituitary-dependent cushing's disease 30.7 SST GHRH
7 diarrhea 30.6 SST PYY NTS IFNA2 CALCA
8 meckel diverticulum 30.5 SST CHGA
9 tricuspid valve stenosis 30.4 SST CHGA
10 appendix adenocarcinoma 30.4 SYP CHGA
11 patent foramen ovale 30.3 SST CHGA CALCA
12 pituitary tumors 30.2 SST IGF1
13 pituitary adenoma 30.2 SST IGF1 GHRH CHGA
14 pulmonary valve insufficiency 30.2 SST CHGA
15 neurofibromatosis, type i 30.2 SST SDHD ENO2
16 ampulla of vater benign neoplasm 30.2 SYP SST ENO2 CHGA
17 gastrinoma 30.2 SYP SST CHGA
18 orbital cancer 30.1 SYP ENO2
19 benign ileal neoplasm 30.1 SYP SST CHGA
20 acromegaly 30.1 SST IGF1 GHRH
21 glucagonoma 30.1 SST CHGA
22 malignant teratoma 30.0 SYP ENO2
23 adenoma 30.0 SYP SST IGF1 GHRH CHGA
24 jejunal neoplasm 30.0 SYP ENO2
25 lung oat cell carcinoma 30.0 SYP ENO2 CHGA
26 ectopic cushing syndrome 30.0 SYP SST CHGA CALCA
27 parathyroid adenoma 30.0 SYP CHGA CALCA
28 hyperinsulinemic hypoglycemia, familial, 2 30.0 SST CHGA
29 sclerosing hemangioma 30.0 SYP CHGA
30 prolactinoma 30.0 SST IGF1 CHGA
31 tubular adenocarcinoma 30.0 SYP ENO2 CHGA
32 pulmonary sclerosing hemangioma 30.0 SYP CHGA
33 functioning pituitary adenoma 30.0 SST IGF1 GHRH
34 zollinger-ellison syndrome 30.0 SST NTS GHRH CHGA
35 amenorrhea 30.0 PYY NPY IGF1
36 irritable bowel syndrome 29.9 SST PYY CHGA
37 rectum neuroendocrine neoplasm 29.9 SYP SST
38 middle ear adenoma 29.9 SYP ENO2 CHGA
39 gallbladder disease 29.9 VEGFA SST PYY
40 status epilepticus 29.9 SST NPY ENO2
41 small cell cancer of the lung 29.9 SYP SST ENO2 CHGA CALCA
42 thyroid carcinoma, familial medullary 29.9 SST CHGA CALCA
43 hyperinsulinemic hypoglycemia 29.8 SYP SST CHGA
44 intracranial meningioma 29.8 VEGFA SST
45 mediastinal cancer 29.8 SYP ENO2 CHGA
46 leptin deficiency or dysfunction 29.8 PYY NPY IGF1 GHRH
47 lung benign neoplasm 29.8 SYP ENO2 CHGA
48 cauda equina syndrome 29.8 SYP CALCA
49 mccune-albright syndrome 29.7 SST IGF1 GHRH
50 hyperthyroidism 29.7 SST IGF1 CALCA

Graphical network of the top 20 diseases related to Carcinoid Syndrome:



Diseases related to Carcinoid Syndrome

Symptoms & Phenotypes for Carcinoid Syndrome

Human phenotypes related to Carcinoid Syndrome:

58 30 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 night sweats 58 30 Frequent (33%) Frequent (79-30%)
HP:0030166
2 small intestine carcinoid 58 30 Frequent (33%) Frequent (79-30%)
HP:0006722
3 episodic abdominal pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0002574
4 intestinal carcinoid 58 30 Frequent (33%) Frequent (79-30%)
HP:0006723
5 erythematous plaque 58 30 Frequent (33%) Frequent (79-30%)
HP:0025474
6 protracted diarrhea 58 30 Frequent (33%) Frequent (79-30%)
HP:0004385
7 nausea and vomiting 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002017
8 elevated hepatic transaminase 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002910
9 asthma 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002099
10 tricuspid regurgitation 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0005180
11 facial telangiectasia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0007380
12 heart murmur 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030148
13 palpitations 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001962
14 epiphora 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0009926
15 chronic noninfectious lymphadenopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002730
16 right ventricular failure 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001708
17 increased serum serotonin 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003144
18 bronchospasm 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0025428
19 abnormal b-type natriuretic peptide level 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0031138
20 rhinorrhea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0031417
21 myopathy 58 30 Very rare (1%) Very rare (<4-1%)
HP:0003198
22 paraganglioma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002668
23 atypical pulmonary carcinoid tumor 58 30 Very rare (1%) Very rare (<4-1%)
HP:0030446
24 hepatic necrosis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002605
25 lack of bowel sounds 58 30 Very rare (1%) Very rare (<4-1%)
HP:0030145
26 pulmonary carcinoid tumor 58 Occasional (29-5%)
27 carcinoid tumor 58 Obligate (100%)

MGI Mouse Phenotypes related to Carcinoid Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.03 CALCA CHGA ENO2 GHRH IGF1 NPY
2 normal MP:0002873 9.97 CALCA IFNA2 IGF1 NPY PYY SDHD
3 growth/size/body region MP:0005378 9.65 CHGA ENO2 GHRH IGF1 NPY NTS
4 adipose tissue MP:0005375 9.63 GHRH IGF1 NPY NTS PYY SST
5 behavior/neurological MP:0005386 9.32 CALCA ENO2 GHRH NPY NTS PYY

Drugs & Therapeutics for Carcinoid Syndrome

Drugs for Carcinoid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyproheptadine Approved Phase 3 129-03-3 2913
2
Histamine Approved, Investigational Phase 3 51-45-6 774
3
Levoleucovorin Approved, Experimental, Investigational Phase 2, Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
4
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
5
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
6
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 43805 11947679 6857599
7
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
8 3-Iodobenzylguanidine Phase 3
9 Immunoglobulins, Intravenous Phase 3
10 Immunoglobulins Phase 3
11 Antibodies, Monoclonal Phase 3
12 Antibodies Phase 3
13 Mitogens Phase 3
14 Immunoglobulin G Phase 3
15 Endothelial Growth Factors Phase 3
16 Anti-Allergic Agents Phase 3
17
Histamine phosphate Phase 3 51-74-1 134614
18 Histamine H1 Antagonists Phase 3
19 Histamine Antagonists Phase 3
20 Antineoplastic Agents, Immunological Phase 2, Phase 3
21 Immunosuppressive Agents Phase 2, Phase 3
22 Vitamins Phase 2, Phase 3
23 Folate Phase 2, Phase 3
24 Vitamin B9 Phase 2, Phase 3
25 Trace Elements Phase 2, Phase 3
26 Vitamin B Complex Phase 2, Phase 3
27 Antidotes Phase 2, Phase 3
28 Micronutrients Phase 2, Phase 3
29 Protective Agents Phase 2, Phase 3
30 Neurotransmitter Agents Phase 3
31 Angiogenesis Inhibitors Phase 2, Phase 3
32 5-Hydroxytryptophan Phase 3
33 Serotonin Receptor Agonists Phase 3
34
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
35
Lactitol Approved, Investigational Phase 1, Phase 2 585-86-4 157355
36
Lenograstim Approved, Investigational Phase 2 135968-09-1
37
Hydroxyurea Approved Phase 2 127-07-1 3657
38
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
41
Peginterferon alfa-2b Approved Phase 2 215647-85-1, 99210-65-8
42
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
43
Streptozocin Approved, Investigational Phase 2 18883-66-4, 66395-18-4 29327
44
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
45
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
46
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
47
Floxuridine Approved Phase 2 50-91-9 5790
48
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
49
Racepinephrine Approved, Vet_approved Phase 2 51-43-4, 329-65-7 838 5816
50
Everolimus Approved Phase 2 159351-69-6 70789204 6442177

Interventional clinical trials:

(show top 50) (show all 154)
# Name Status NCT ID Phase Drugs
1 Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation A Prospective Interventional Trial of Patients With Neuro-endocrine Tumors With Carcinoid Syndrome Receiving Octreotide LAR Terminated NCT04140409 Phase 4 Sandostatin
2 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
3 A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
4 A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
5 A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
6 A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606) Completed NCT02026063 Phase 3 Telotristat etiprate
7 A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
8 A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-related Symptoms Are Inadequately Controlled by Somatostatin Analogues. Completed NCT00690430 Phase 3 Pasireotide;Octreotide
9 A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Completed NCT01578239 Phase 3 Octreotide LAR;177Lu-DOTA0-Tyr3-Octreotate
10 Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET) Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
11 Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients Active, not recruiting NCT00569127 Phase 3 Octreotide Acetate
12 Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial Not yet recruiting NCT04820751 Phase 3 Cyproheptadine Hydrochloride 4 MG
13 A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
14 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Terminated NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
15 Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Terminated NCT00227136 Phase 3 5-Hydroxy-Tryptamine
16 Randomized Phase III Clinical Trial of Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Withdrawn NCT04065165 Phase 3 Telotristat Ethyl;Lanreotide
17 Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon α-2b Withdrawn NCT01860742 Phase 3 Interferon alpha-2b;177Lu-DOTATATE
18 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Unknown status NCT02038738 Phase 1, Phase 2 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
19 A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS Unknown status NCT01731925 Phase 2 Lanreotide;Placebo (for sunitinib);Sunitinib
20 A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2 RAD001 (everolimus, Afinitor®)
21 A Phase 2 Study Evaluating a Proprietary Amino Acid Based Medical Food (Enterade®) in Patients With Quality of Life Limiting Diarrhea Due to Carcinoid Syndrome and Other Neuroendocrine Tumors (NET). Completed NCT03722511 Phase 2
22 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-Acting Release Depot Therapy Completed NCT00853047 Phase 2 Telotristat etiprate;Octreotide LAR Depot;Placebo
23 A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Telotristat etiprate
24 Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors Completed NCT02259725 Phase 2 regorafenib
25 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
26 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
27 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
28 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
29 Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
30 A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas Completed NCT00093782 Phase 2 temsirolimus
31 Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
32 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
33 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
34 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
35 A Phase II Study of Protracted Infusional 5-Fluorouracil Plus Alpha Interferon for Advanced Metastatic Carcinoid Completed NCT00002470 Phase 2 fluorouracil
36 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
37 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
38 Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) Completed NCT00027638 Phase 2 thalidomide
39 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
40 A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT00780663 Phase 2 Quarfloxin
41 Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT02575300 Phase 2 Ibrutinib
42 A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-endocrine Tumors Completed NCT00688623 Phase 2 Everolimus
43 Safety & Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging & Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT. Completed NCT01619865 Phase 1, Phase 2 68Ga-DOTATOC PET/CT
44 An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2 Pasireotide (SOM230)
45 EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
46 A Phase 1-2 Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With rhuMAb VEGF (Bevacizumab) in Patients With Locally Advanced or Metastatic Carcinoid Tumors Completed NCT00328497 Phase 2 Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
47 Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Completed NCT02441062 Phase 2 68Ga-DOTATOC PET/CT
48 Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
49 A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT01024387 Phase 2 AMG 479
50 A Phase II Study of Axitinib in Advanced Carcinoid Tumors Completed NCT01435122 Phase 2 Axitinib

Search NIH Clinical Center for Carcinoid Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2b

Genetic Tests for Carcinoid Syndrome

Anatomical Context for Carcinoid Syndrome

Organs/tissues related to Carcinoid Syndrome:

MalaCards : Heart, Lung, Small Intestine, Skin, Liver, Appendix, Lymph Node

Publications for Carcinoid Syndrome

Articles related to Carcinoid Syndrome:

(show top 50) (show all 8096)
# Title Authors PMID Year
1
International trends in pulmonary neuroendocrine cancer studies:a scientometric study. 62 41
36287436 2022
2
Patients with ectopic ACTH syndrome might have a better prognosis in bronchopulmonary carcinoids with lymph node metastasis received radical surgery: a single-centre retrospective study in the last 22 years in China. 41
36348311 2022
3
Clinical characteristics and survival outcomes in patients with ovarian strumal carcinoid. 41
36280824 2022
4
Middle Ear Carcinoid Tumor With External Auditory Canal Extension: A Case Report. 62
33470831 2023
5
Does Examined Lymph Node Count Influence Survival in Surgically Resected Early‑stage Pulmonary Typical Carcinoid Tumors? 62
36413680 2022
6
The utility of near infrared autofluorescence imaging for detecting small bowel carcinoid tumors in comparison to DOTATATE PET: A pilot study. 62
35960603 2022
7
A carcinoid tumor of the middle ear masquerading as a glomus tympanicum presenting with temporal lobe hemorrhage in a 70-year-old woman: Case report and review of the literature. 62
35905789 2022
8
Hedinger Syndrome with Intraoperative Carcinoid Crisis - Understanding the Pathophysiology for a Successful Management. 62
34673518 2022
9
Management of Carcinoid Syndrome and Carcinoid Crisis in the Perioperative Environment. 62
36273967 2022
10
Sublobar Resection Versus Lobectomy for Early-Stage Pulmonary Carcinoid Tumors ≤3 cm in Size: A SEER Population-Based Study. 62
33196487 2022
11
Imaging of Lung Cancer Staging. 62
35815631 2022
12
Neuroendocrinology of the lung revealed by single-cell RNA sequencing. 62
36469459 2022
13
Toward Personalized Medicine: One Chelator for Imaging and Therapy with Lutetium-177 and Actinium-225. 62
36382991 2022
14
Peptide Receptor Radionuclide Therapy. 62
36198028 2022
15
Primary testicular neuroendocrine tumor with liver lymph node metastasis: A case report and review of the literature. 62
36405286 2022
16
NOL4 is a novel nuclear marker of small cell carcinoma and other neuroendocrine neoplasms. 62
36282054 2022
17
Ectopic adrenocorticotropic hormone-secreting carcinoid with solitary cryptococcosis in the lungs. 62
36196010 2022
18
Atypical Bronchial Carcinoid Tumor Revealed by Liver Biopsy. 62
36475219 2022
19
Strumal Carcinoid Tumor of the Ovary: Report of Rare Occurrence with Review of Literature. 62
36359551 2022
20
Volume Doubling Time of Pulmonary Carcinoid Tumors Measured by Computed Tomography. 62
35922364 2022
21
AN INCIDENTALLY DETECTED CASE OF ATYPICAL BRONCHIAL CARCINOID IN STRESS MYOCARDIAL PERFUSION SPECT/CT. 62
36195445 2022
22
Atypical pulmonary carcinoid tumor encapsulated by a Staphylococcus aureus infection. 62
36193652 2022
23
Commentary: Sunlight, lasers, or knives? How to treat typical carcinoid tumors. 62
36276708 2022
24
Atypical Carcinoid Syndrome in a Patient Presenting With Pericarditis and Supraventricular Tachycardia: A Case Report. 62
36381843 2022
25
Carcinoid Tumor of the Cecal Appendix. 62
36447686 2022
26
Commentary: Endobronchial treatment of central airway typical carcinoid tumors: The devil is in the details. 62
36276665 2022
27
The Unusual Suspect of Carcinoid Tumor: Salivary Gland in Airway Anyone? 62
36228058 2022
28
Anesthetic Management of Gastrointestinal Carcinoid Tumors: A Case Report. 62
36173796 2022
29
Platin‑based chemotherapy does not improve survival in patients with non‑metastatic resected typical carcinoid tumors. 62
36157316 2022
30
Large-cell Neuroendocrine Carcinoma of the Lung with Carcinoid Syndrome: A Case Report. 62
36198589 2022
31
Small bowel carcinoid tumor causing intestinal ischemia: A case report with review of the literature. 62
35936884 2022
32
A Case of Primary Insular Ovarian Carcinoid Tumor with Hyperandrogenism and Carcinoid Heart Disease. 62
36181247 2022
33
Carcinoid Heart Disease From a Primary Liver Carcinoid Tumor. 62
36299646 2022
34
Repurposed Effect of 177Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma. 62
36290871 2022
35
A rare case of poorly differentiated mixed neuroendocrine-nonneuroendocrine tumor of the caecum with long term survival: A case report. 62
36270345 2022
36
Siegfried Oberndorfer (1874-1944) - A "prophet" not recognized in his own land. 62
35849966 2022
37
Multimodality Imaging of the Neglected Valve: Role of Echocardiography, Cardiac Magnetic Resonance and Cardiac Computed Tomography in Pulmonary Stenosis and Regurgitation. 62
36286372 2022
38
Multiple Endocrine Neoplasia Type 1 62
30725665 2022
39
A Case Report of Rare Synchronous Esophageal Malignancies With Dissimilar Histology: Squamous Cell Carcinoma and Small Cell Carcinoma. 62
36321021 2022
40
Postoperative inverted intercostal hernia incidentally detected by chest computed tomography in a patient with COVID-19. 62
35846512 2022
41
Novel scoring system guiding the incorporation of adjuvant RT for neuroendocrine neoplasms treated with surgical resection followed by chemotherapy. 62
36114862 2022
42
Right ventricular failure: a comorbidity or a clinical emergency? 62
34826024 2022
43
In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. 62
35503379 2022
44
Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art. 62
36186753 2022
45
Simultaneous pathological findings in biopsy specimens of patients with surgically resected lung carcinoids and their role in survival. 62
35949610 2022
46
Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors. 62
36230651 2022
47
Sclerosing pneumocytoma with carcinoid tumorlets and neuroendocrine cell hyperplasia. 62
36075662 2022
48
Neuroendocrine Tumor Causing Carcinoid Syndrome in the Elderly. 62
36324346 2022
49
Total en bloc spondylectomy for the L5 metastasis of a carcinoid tumor: illustrative case. 62
36088551 2022
50
Collision lung tumor associating typical carcinoid tumor to sclerosing hemangioma. 62
35957793 2022

Variations for Carcinoid Syndrome

Expression for Carcinoid Syndrome

Search GEO for disease gene expression data for Carcinoid Syndrome.

Pathways for Carcinoid Syndrome

GO Terms for Carcinoid Syndrome

Cellular components related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.26 VEGFA SST PYY NTS NPY IGF1
2 extracellular space GO:0005615 10.16 CALCA CHGA ENO2 GHRH IFNA2 IGF1
3 terminal bouton GO:0043195 9.56 SYP NPY GHRH CALCA
4 neuronal dense core vesicle GO:0098992 9.1 SST NPY CHGA CALCA

Biological processes related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.91 SST IFNA2 GHRH CALCA
2 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.76 IGF1 GHRH
3 regulation of blood pressure GO:0008217 9.73 NPY CHGA CALCA
4 negative regulation of neuron death GO:1901215 9.73 CHGA ENO2 NPY
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 VEGFA IGF1 IFNA2
6 intestinal epithelial cell differentiation GO:0060575 9.71 PYY NPY
7 response to heat GO:0009408 9.63 SST IGF1 CALCA
8 feeding behavior GO:0007631 9.43 PYY NPY CALCA
9 neuropeptide signaling pathway GO:0007218 9.23 CALCA NPY NTS PYY

Molecular functions related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.56 PYY NTS NPY GHRH
2 neuropeptide Y receptor binding GO:0031841 9.46 NPY PYY
3 hormone activity GO:0005179 9.36 SST PYY NPY IGF1 GHRH CALCA

Sources for Carcinoid Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....